title: Lower levels of urinary 2-hydroxyestrogens in polycystic ovary syndrome.
abstract: BACKGROUND
  Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells.
  
  
  OBJECTIVE
  The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS.
  
  
  METHODS
  Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry.
  
  
  METHODS
  The study was conducted at a tertiary university referral center.
  
  
  METHODS
  Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects.
  
  
  METHODS
  COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured.
  
  
  RESULTS
  Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031).
  
  
  CONCLUSIONS
  Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.
authors.affiliation: Department of Obstetrics and Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-0587, USA.
authors.forename: Sana
authors.initials: S
authors.lastname: Salih
authors.forename: Xia
authors.initials: X
authors.lastname: Xu
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Veenstra
authors.forename: Antoni J
authors.initials: AJ
authors.lastname: Duleba
authors.forename: Hala
authors.initials: H
authors.lastname: Fouad
authors.forename: Manubai
authors.initials: M
authors.lastname: Nagamani
authors.forename: Ayman
authors.initials: A
authors.lastname: Al-Hendy
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002394:Catechol O-Methyltransferase / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D004797:Enzyme-Linked Immunosorbent Assay; D004967:Estrogens / Q000652:urine; D002393:Estrogens, Catechol / Q000652:urine*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D006080:Ovarian Follicle / Q000201:enzymology / Q000473:pathology; D010053:Ovary / Q000201:enzymology; D011085:Polycystic Ovary Syndrome / Q000652:urine*; D021241:Spectrometry, Mass, Electrospray Ionization
chemical_list: D004967:Estrogens; D002393:Estrogens, Catechol; D002394:Catechol O-Methyltransferase